Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation
Despite combination antiretroviral therapy (cART), acquired immunodeficiency syndrome (AIDS), predominantly caused by the human immunodeficiency virus type 1 (HIV-1), remains incurable. The barrier to a cure lies in the virus' ability to establish a latent infection in HIV/AIDS patients. Unsurp...
Main Authors: | Maxime J. Jean, Tsuyoshi Hayashi, Huachao Huang, Justin Brennan, Sydney Simpson, Andrei Purmal, Katerina Gurova, Michael C. Keefer, James J. Kobie, Netty G. Santoso, Jian Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-10-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2017.02007/full |
Similar Items
-
Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
by: Sabrina Dallavalle, et al.
Published: (2021-06-01) -
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
by: Timur I. Fetisov, et al.
Published: (2023-01-01) -
Predictors of SIV recrudescence following antiretroviral treatment interruption
by: Mykola Pinkevych, et al.
Published: (2019-10-01) -
HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
by: Sushant Khanal, et al.
Published: (2021-02-01) -
Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-04-01)